Tyrosinase (T311)

„[1] Chen YT, Stockert E, Tsang S et al. (1995): Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci U S A. 92(18):8125-9.
[2] Clarkson KS, Sturdgess IC and Molyneux AJ (2001): The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 54(3):196-200.
[3] Avogadri F, Gnjatic S, Tassello J et al. (2016): Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2. Am J Dermatopathol. 38(3):201-7.
[4] Jäger E, Ringhoffer M, Altmannsberger M et al. (1997): Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer. 71(2):142-7.
[5] Sheffield MV, Yee H, Dorvault CC et al. (2002): Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol. 118(6):930-6.
[6] Shidham VB, Qi D, Rao RN et al. (2003): Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with ‚MCW melanoma cocktail‘–a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase. BMC Cancer. 3:15.“